# US 2025/0360209 A1 · Anti-ctla-4 antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0360209 A1
- Document ID: US20250360209A1
- Status: Published application
- Kind: A1
- Application number: 19/048,583
- Filed: 2025-02-07
- Published: 2025-11-27
- Earliest claimed: 2020-09-24
- Assignees: Agenus Inc.; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center
- Applicants: Agenus Inc.; Ludwig Institute for Cancer Research Ltd.; Memorial Sloan Kettering Cancer Center
- Inventors: Marc van Dijk; Cornelia Anne Mundt; Gerd Ritter; David Schaer; Jedd David Wolchok; Taha Merghoub; Nicholas Stuart Wilson; David Adam Savitsky; Mark Arthur Findeis; Dennis John Underwood; Jean-Marie Cuillerot; Igor Proscurshim; Olga Shebanova
- Web page: https://patentgrep.com/patent/US20250360209A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/04: specific for metastasis
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/572: {cytotoxic response}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

## Claims

### Claim at position 1

-46. (canceled)

### Claim 47

A method of increasing T cell activation in response to an antigen in a subject, the method comprising administering to the subject an effective amount of an isolated antibody that specifically binds to human CTLA-4, the antibody comprising:
a heavy chain variable region (VH) comprising the complementarity determining regions CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 20; and
and a light chain variable region (VL) comprising the complementarity determining regions CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9,
wherein the CDRH1, CDRH2, and CDRH3 amino acid sequences of the antibody are not SEQ ID NOs: 10, 11, and 13, respectively.

### Claim 48 (depends on 47)

The method of claim 47, wherein:
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 2; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 4; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9; or
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 5; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 6; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 7; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9; or
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 8; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9.

### Claim 49 (depends on 47)

The method of claim 47, wherein:
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 18, 19, 15, 16, and 17, respectively;
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 11, 14, 15, 16, and 17, respectively;
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 12, 13, 15, 16, and 17, respectively; or
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 12, 14, 15, 16, and 17, respectively.

### Claim 50 (depends on 47)

The method of claim 47, wherein:
the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, and 8; and/or
the VL comprises the amino acid sequence set forth in SEQ ID NO: 9.

### Claim 51 (depends on 47)

The method of claim 47, wherein the VH and the VL comprise the amino acid sequences set forth in SEQ ID NOs: 2 and 9; 4 and 9; 5 and 9; 6 and 9; 7 and 9; or 8 and 9, respectively.

### Claim 52 (depends on 47)

The method of claim 47, wherein:
the antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 23, 24, 25, and 26; and/or
the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 27.

### Claim 53 (depends on 47)

The method of claim 47, wherein the antibody comprises a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 23 and 27; 24 and 27; 25 and 27; or 26 and 27, respectively.

### Claim 54

A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of an isolated antibody that specifically binds to human CTLA-4, the antibody comprising:
a heavy chain variable region (VH) comprising the complementarity determining regions CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 20; and
and a light chain variable region (VL) comprising the complementarity determining regions CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9,
wherein the CDRH1, CDRH2, and CDRH3 amino acid sequences of the antibody are not SEQ ID NOs: 10, 11, and 13, respectively.

### Claim 55 (depends on 54)

The method of claim 54, wherein:
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 2; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 4; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9; or
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 5; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 6; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9;
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 7; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9; or
the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 8; and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 9.

### Claim 56 (depends on 54)

The method of claim 54, wherein:
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 18, 19, 15, 16, and 17, respectively;
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 11, 14, 15, 16, and 17, respectively;
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 12, 13, 15, 16, and 17, respectively; or
CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 of the antibody comprise the amino acid sequences set forth in SEQ ID NOs: 10, 12, 14, 15, 16, and 17, respectively.

### Claim 57 (depends on 54)

The method of claim 54, wherein the VH and the VL comprise the amino acid sequences set forth in SEQ ID NOs: 2 and 9; 4 and 9; 5 and 9; 6 and 9; 7 and 9; or 8 and 9, respectively.

### Claim 58 (depends on 54)

The method of claim 54, wherein the antibody comprises a heavy chain and a light chain comprising the amino acid sequences set forth in SEQ ID NOs: 23 and 27; 24 and 27; 25 and 27; or 26 and 27, respectively.

### Claim 59 (depends on 54)

The method of claim 54, wherein the cancer is:
(a) a metastatic or locally advanced tumor;
(b) a solid tumor; and/or
(c) refractory to a standard therapy.

### Claim 60 (depends on 54)

The method of claim 54, wherein the cancer is selected from the group consisting of B cell lymphoma, basal cell carcinoma, bladder cancer, blastoma, brain metastasis, breast cancer, Burkitt lymphoma, cervical cancer, colon cancer, colorectal cancer, cutaneous squamous cell carcinoma, endometrial carcinoma, esophageal cancer, Ewing sarcoma, follicular lymphoma, gastric cancer, gastroesophageal junction carcinoma, gastrointestinal cancer, glioblastoma, glioma, head and neck cancer, hepatic metastasis, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, laryngeal cancer, leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, lymphoblastic lymphoma, lymphoma, mantle cell lymphoma, metastatic cancer, myeloma, neuroblastoma, ocular melanoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, metastatic hormone refractory cancer, renal cell carcinoma, salivary gland carcinoma, sarcoma, skin cancer, soft tissue sarcoma, solid tumor, squamous cell carcinoma, synovia sarcoma, testicular cancer, thyroid cancer, transitional cell cancer, uveal melanoma, verrucous carcinoma, vulval cancer, and Waldenstrom macroglobulinemia.

### Claim 61 (depends on 54)

The method of claim 54, wherein the antibody is administered as the first cancer therapy after:
(a) diagnosis of tumor progression that has occurred despite previous treatment of the cancer with a different cancer therapy; or
(b) diagnosis of toxicity of a different cancer therapy.

### Claim 62 (depends on 54)

The method of claim 54, wherein the antibody is administered at a dose of 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, or 10 mg/kg.

### Claim 63 (depends on 54)

The method of claim 54, wherein the antibody is administered at an interval of once every two weeks, once every three weeks, once every four weeks, once every six weeks, or once every twelve weeks.

### Claim 64 (depends on 54)

The method of claim 54, further comprising administering an additional therapeutic agent to the subject.

### Claim 65 (depends on 64)

The method of claim 64, wherein the additional therapeutic agent is selected from the group consisting of a chemotherapeutic, a checkpoint targeting agent, an inhibitor of indoleamine-2,3-dioxygenase (IDO), and a vaccine.

### Claim 66 (depends on 65)

The method of claim 65, wherein the checkpoint targeting agent is selected from the group consisting of an antagonist anti-PD-1 antibody, an antagonist anti-PD-L1 antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-CTLA-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-CEACAM 1 antibody, an agonist anti-GITR antibody, an agonist anti-OX40 antibody, and an agonist anti-CD137 antibody.
